Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Epetraborole

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    AN2 Therapeutics To Launch 90-Patient Trial For Epetraborole
    AN2 Therapeutics To Launch 90-Patient Trial For Epetraborole

    12 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260112479198/en/AN2-Therapeutics-Announces-FDA-Clearance-to-Proceed-with-90-Patient-Investigator-Initiated-Trial-IIT-of-Epetraborole-in-Patients-with-M.-abscessus-Lung-Disease

    BUSINESSWIRE
    12 Jan 2026
    Share Share
    AN2 Therapeutics Reports Q2 2024 Results And Recent Highlights
    AN2 Therapeutics Reports Q2 2024 Results And Recent Highlights

    13 Aug 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240813783660/en

    BUSINESSWIRE
    13 Aug 2024
    Share Share
    AN2 Therapeutics shares fall after pausing lung disease study enrollment
    AN2 Therapeutics shares fall after pausing lung disease study enrollment

    13 Feb 2024

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/an2-therapeutics-pause-lung-disease-study-enrollment-2024-02-12/

    REUTERS
    13 Feb 2024
    Share Share
    AN2 Therapeutics commences Phase 2/3 Clinical Trial Evaluating Epetraborole
    AN2 Therapeutics commences Phase 2/3 Clinical Trial Evaluating Epetraborole

    13 Sep 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230913252729/en

    BUSINESSWIRE
    13 Sep 2023
    Share Share
    AN2 Therapeutics Initiates Pivotal PII/III Trial Evaluating Epetraborole
    AN2 Therapeutics Initiates Pivotal PII/III Trial Evaluating Epetraborole

    29 Jun 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/06/29/2471129/0/en/AN2-Therapeutics-Initiates-Pivotal-Phase-2-3-Trial-Evaluating-Epetraborole-for-Treatment-Refractory-MAC-Lung-Disease.html

    GLOBENEWSWIRE
    29 Jun 2022
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.